Advanced Biotherapy
Advanced Biotherapy enters into share purchase and debt restructure agreement
Published in Pharma Investments, Ventures and Law Weekly, October 1st, 2006
In addition, Kiphart and other debt holders will convert their debt at $.015 per share resulting in Kiphart having personal control over approximately 80% of ADVB shares. Immediately following the infusion of capital, payables will be retired by both the use of cash as well as the conversion of some portion to stock at the same $.015 price. It is estimated that ADVB will be virtually debt free and have approximately $6.0 million in cash,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AGA Medical
AGA Medical files suit in Germany alleging patent infringement - Ablynx
Ablynx completes EUR 40 million series C financing - Affymetrix
Affymetrix files restated financial statements - Amylin Pharmaceuticals
Amylin converts all outstanding 2.25% convertible senior notes due 2008 - Bradley Pharmaceuticals
Bradley Pharmaceuticals announces initiatives to enhance shareholder value - Cepheid
Cepheid awarded $3.3 million STTR NIH/NIAID grant for TB test development - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
